in a clinical trial that is still in progress , we studied the ability of deprenyl and tocopherol , antioxidative agents that act through complementary mechanisms , to delay the onset of disability necessitating levodopa therapy ( the primary end point ) in patients with early , untreated parkinson 's disease .
C0023570
levodopa
C0030567
parkinson 's disease